NCT07750717 Bedside Spirometry for Acute Lung Injury

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2026-10-16 with a primary completion date of 2026-10-16.

Brief Summary

The diagnosis of Acute Respiratory Distress Syndrome (ARDS) is a syndromic diagnosis that groups together patients who may have very different prognoses and respond differently to the same therapies. Additionally, non-invasive ventilation (NIV) has shown highly contrasting results in the early management of ARDS. One of the predictive criteria for NIV failure is an excessively high tidal volume during non-invasive ventilation. SPIRALI is a pilot study evaluating the relevance of a respiratory physiology parameter, the tidal volume relative to the theoretical ideal body weigh, in the phenotypic classification of non-intubated ARDS patients. In this initial approach, the investigators will compare the tidal volume during high-flow oxygen therapy with the tidal volume obtained under NIV (after applying a settings optimization algorithm). The investigators hypothesize that if tidal volume is linked to each situation, the same patients will exhibit a high tidal volume both during spontaneous ventilation and under NIV.

Eligibility Criteria

Inclusion Criteria: * Patient over 18 years of age; * Patient hospitalized in intensive care for less than 24 hours; * Patient with severe hypoxemic acute respiratory failure characterized by a PaO2/FiO2 ratio \< 300 mmHg and \> 150 mmHg under high-flow oxygen therapy at 60 L/min; * Patient able to cooperate with the spirometry test; * Patient able to follow the protocol and having given their informed written consent to participate in the study; * Patient who has been informed that his or her health data will be subject to quality control as part of this clinical investigation and of his or her right to object to such control, and who has not exercised that right, * Patient affiliated with the social security system or entitled to benefits; Exclusion Criteria: * Patients with an indication for intubation; * Patients with a contraindication for or who refuse NIV; * Patients with hemodynamic instability requiring vasopressor support greater than 0.25 μg/kg/min of norepinephrine; * Patients with a Glasgow score \< 15; * Patients with hypercapnia (PaCO2 \> 45 mmHg); * Patients who requires an FiO2 of ≥ 80% to achieve an SpO2 of ≥ 94%;; * Patients with cardiogenic pulmonary edema; * Patients who have already undergone a session of NIV in intensive care during this stay; * Patients with chronic respiratory failure (home oxygen therapy or home non-invasive ventilation (excluding indications solely for sleep apnea syndrome)); * Patients who have recently had a pneumothorax; * Patients who have recently undergone eye surgery (e.g., cataract surgery) or throat surgery; * Patients with significant arterial disease: recent heart attack, pulmonary embolism, poorly controlled hypertension despite treatment, etc. * Patients already included in the study; * Pregnant women, women in labor, or women who are breastfeeding; * Patients under guardianship, conservatorship, or deprived of their liberty; * Patients under an activated future protection mandate; * Patients under family authorization; * Patients under judicial protection;

Contact & Investigator

Frequently Asked Questions

Related Trials